Development and Validation of an HPLC Method for the Simultaneous Detection of Nirmatrelvir and Ritonavir in Pharmaceutical Formulations

Abstract

The simultaneous estimation of the Nirmatrelvir and Ritonavir in pharmaceutical dosage form. Chromatogram was run through Discovery C18 250 x 4.6 mm, 5m. Mobile phase containing Buffer KH2PO4: Acetonitrile taken in the ratio 65:35 was pumped through column at a flow rate of 0.9 ml/min.. Temperature was maintained at 30°C. Optimized wavelength selected was 242 nm. Nirmatrelvir and Ritonavir were eluted at 2.251 min and 2.820 min respectively. %RSD of the Nirmatrelvir and Ritonavir were and found to be 0.2 and 0.3 respectively. %Recovery was obtained as 99.33% and 99.49% for Nirmatrelvir and Ritonavir respectively. LOD, LOQ values obtained from regression equations of Nirmatrelvir and Ritonavir were 0.09, 0.26 and 0.07, 0.20 respectively. Regression equation of Nirmatrelvir is y = 40331x + 7783.3, and y = 47638x + 4515.3 of Ritonavir.